EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Thulium Laser Vaporization of the Prostate: A Transurethral Procedure for Benign Prostatic Hyperplasia

Daisuke Gotoh iD, Kazumasa Torimoto, Akira Tachibana, Nobutaka Nishimura, Mitsuru Tomizawa, Kenta Onishi, Yosuke Morizawa, Shunta Hori, Yasushi Nakai, Makito Miyake iD, Kiyohide Fujimoto

LUTS: Lower Urinary Tract Symptoms · 2025

DOI: 10.1111/luts.70012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift LUTS: Lower Urinary Tract Symptoms, 2025. Verfasst von Daisuke Gotoh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nara Medical University, Kashihara, Japan. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Thulium, Laser Therapy, Transurethral Resection of Prostate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To explore the efficacy and safety of thulium laser vaporization of the prostate (ThuVAP) for benign prostatic hyperplasia (BPH) at Nara Medical University from 2022 to 2024.

Methods

Patients with BPH who underwent ThuVAP at the Department of Urology, Nara Medical University, between January 01, 2022 and April 30, 2024, were enrolled. Patient background, presurgical pressure flow study results, treatment efficacy, and safety were retrospectively evaluated.

Results

The study included 32 patients; the median age was 74.5 years at surgery. The total International Prostate Symptom Score and quality of life were significantly lower at 4 weeks after surgery than at baseline. They continued to decrease at 12 and 24 weeks. The maximum flow rate was significantly higher at 4 weeks after surgery than at baseline; it continued to increase for 12 and 24 weeks. The postvoid residual (PVR) was significantly lower at 4 weeks after surgery than at baseline and continued to decrease at 12 and 24 weeks. Intravesical prostatic protrusion and prostate volume were positively correlated with the surgery and laser usage times. Two patients experienced temporary urinary retention, and two underwent transurethral electrocoagulation for postoperative bleeding.

Conclusions

Our data confirm ThuVAP as an effective and safe treatment for BPH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic HyperplasiaThuliumLaser TherapyTransurethral Resection of ProstateLasers, Solid-StateHumansMaleAgedRetrospective StudiesTreatment OutcomeAged, 80 and overMiddle AgedQuality of LifeProstate

Stichwörter der Autor:innen

BPHThuVAPbenign prostatic hyperplasiasurgerythulium laser vaporization of the prostate

Substanzen

Thulium

Autor:innen und Institutionen

  • Department of Urology, Nara Medical University, Kashihara, Japan.
  • Department of Urology, Nara Prefecture General Medical Center, Nara, Japan.

ORCID-Profile: Daisuke Gotoh, Makito Miyake

Zitieren

APA

Gotoh, D., Torimoto, K., Tachibana, A., Nishimura, N., Tomizawa, M., Onishi, K., Morizawa, Y., Hori, S., Nakai, Y., Miyake, M., & Fujimoto, K. (2025). Efficacy and Safety of Thulium Laser Vaporization of the Prostate: A Transurethral Procedure for Benign Prostatic Hyperplasia. LUTS: Lower Urinary Tract Symptoms. https://doi.org/10.1111/luts.70012

Vancouver

Gotoh D, Torimoto K, Tachibana A, Nishimura N, Tomizawa M, Onishi K, et al. Efficacy and Safety of Thulium Laser Vaporization of the Prostate: A Transurethral Procedure for Benign Prostatic Hyperplasia. LUTS: Lower Urinary Tract Symptoms. 2025. doi:10.1111/luts.70012

BibTeX
@article{Gotoh2025,
  author = {Gotoh, Daisuke and Torimoto, Kazumasa and Tachibana, Akira and Nishimura, Nobutaka and Tomizawa, Mitsuru and Onishi, Kenta and Morizawa, Yosuke and Hori, Shunta and Nakai, Yasushi and Miyake, Makito and Fujimoto, Kiyohide},
  title = {Efficacy and Safety of Thulium Laser Vaporization of the Prostate: A Transurethral Procedure for Benign Prostatic Hyperplasia},
  journal = {LUTS: Lower Urinary Tract Symptoms},
  year = {2025},
  doi = {10.1111/luts.70012}
}
Kostenlos starten →